| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22028 |
| Drug | Vosoritide |
| Brand | Voxzogo® |
| Indication | For the treatment of genetically confirmed achondroplasia in patients aged two years and older whose epiphyses are not closed. |
| Assessment Process | |
| Rapid review commissioned | 09/05/2022 |
| Rapid review completed | 01/06/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vosoritide compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/07/2022 |
| Pre-submission consultation with Applicant | 26/09/2022 |
| Full submission received from Applicant | 21/03/2023 |
| Preliminary review sent to Applicant | 24/07/2023 |
| NCPE assessment re-commenced | 22/08/2023 |
| Factual accuracy sent to Applicant | 13/09/2023 |
| NCPE assessment re-commenced | 22/09/2023 |
| NCPE assessment completed | 05/10/2023 |
| NCPE assessment outcome | Due to the paucity of clinical outcome data, the very high cost and budget impact in addition to the failure to demonstrate cost-effectiveness the NCPE Review Group recommend that vosoritide not be considered for reimbursement* |
*This recommendation should be considered while also having regards to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.